|
Iterum Therapeutics Plc (NASDAQ: ITRM) |
|
Iterum Therapeutics Plc
ITRM's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Iterum Therapeutics Plc's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 71
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Iterum Therapeutics Plc net loss increased from $-4 millions, to $-6 millions in III. Quarter 2024,
• More on ITRM's Growth
|
|
Iterum Therapeutics Plc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 4.2 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
• More on ITRM's Valuation
|
|
|
|
|
Iterum Therapeutics Plc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 4.2 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
• More on ITRM's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com